[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100388862":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":30,"responsibleParty":56,"collaborators":10,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":10,"maxAge":10,"enrollmentInfo":66,"targetDuration":10,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"H. Lee Moffitt Cancer Center and Research Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants Reviewed by ETB",null,"Participants clinical history, available therapeutic options, and outcome expectations will be presented to the Evolutionary Tumor Board (ETB) along with images and pathology. Strategies and models will be presented regarding additional evolutionary ideas that can be applied.",[13],"Other: Evolutionary Tumor Board (ETB)",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Evolutionary Tumor Board (ETB)","The ETB consists of evolutionary biologists, mathematicians, research scientists, statisticians,data scientists, radiologists, pathologists, oncologists (surgical, radiation, medical, and pediatric), and clinical trial coordinators.The ETB will generate hypotheses, mathematical models, and experiments from the discussion towards further integration of evolutionary ideas towards therapeutic strategies for participants. The ETB will collect data through a chart review regarding adherence and results of ETB recommendation",[9],[20],{"name":21,"affiliation":22,"role":23},"Jingsong Zhang, MD","Moffitt Cancer Center","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Sara Donadelli","CONTACT","813-745-8111","Sara.Donadelli@moffitt.org",[31],{"facility":22,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Tampa","Florida","33613","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-82.45843,27.94752,{"lat":42,"lon":41},[45,46,47,50,52,54],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},{"name":21,"role":23,"phone":10,"phoneExt":10,"email":10},{"name":48,"role":49,"phone":10,"phoneExt":10,"email":10},"Joel Brown, PhD","SUB_INVESTIGATOR",{"name":51,"role":49,"phone":10,"phoneExt":10,"email":10},"Alexander Anderson, PhD",{"name":53,"role":49,"phone":10,"phoneExt":10,"email":10},"Michael Schell, PhD",{"name":55,"role":49,"phone":10,"phoneExt":10,"email":10},"Christine Chung, MD",{"type":57,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100388862","generating-novel-therapeutic-strategies-based-on-evolutionary-tumor-board-100388862",false,"NCT04343365","Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board","Feasibility of Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board in Cancer Patients","Inclusion Criteria:\n\n* Participant must be considered likely incurable given a standard of care. This is inclusive of participants in remission but at high risk of recurrence, with suboptimal responses to previous therapy, or with many potentially beneficial, but not curative options for care.\n* Participant must have a life expectancy greater than 3 months\n* Participant must have an ECOG performance status 0-2\n* Participant and primary Oncologist are willing to consider the therapeutic strategies recommended by the ETB\n* Willingness to be followed over time and allowing collection of clinical data including scans and serial blood sampling.\n\nExclusion Criteria:\n\n* None","ALL",{"count":67,"type":68},35,"ESTIMATED","OBSERVATIONAL","This study will evaluate the ability of a multidisciplinary group, the Evolutionary Tumor Board (ETB), to develop therapeutic strategies in patients without curative options.",[72],"Incurable Disease","2026-03-31",{"date":75,"type":76},"2026-04-01","ACTUAL",{"date":78,"type":76},"2020-05-05",{"date":80,"type":68},"2028-03",{"name":5,"class":6},1]